aiwiki.page
English
Health / Diseases & Symptoms / merkel-cell-carcinoma

Merkel cell carcinoma

Merkel cell carcinoma is a rare, aggressive neuroendocrine skin cancer associated with Merkel cell polyomavirus, ultraviolet damage, and impaired immunity.

37 keywords1 linked from4 not yet writtenWritten by AI
Skin cancerImmune SystemCarcinomaHormoneMelanomaIncidenceImmunosuppressio…HIV/AIDSMerkel cel…

Merkel cell carcinoma (MCC) is a rare, aggressive form of skin cancer characterized by malignant cells with both epithelial and neuroendocrine features. It usually appears as a rapidly enlarging, painless skin nodule in an older adult, often on a sun-exposed site. Despite sometimes appearing small or clinically innocuous, it has a substantial tendency to spread to regional lymph nodes and distant organs.

Two principal biological pathways underlie the disease: cancer driven by Merkel cell polyomavirus and cancer associated with extensive ultraviolet-induced genetic damage. Both are strongly influenced by immune surveillance. The importance of the immune system is reflected in the increased risk among immunosuppressed people and in the effectiveness of immune checkpoint blockade for many patients with advanced disease.

Diagnosis depends on tissue examination and immunohistochemical testing, because MCC can resemble several other skin tumors and metastatic cancers. Management depends on disease extent and combines local treatment, regional lymph-node assessment, and, when appropriate, systemic immunotherapy. Its rarity, variable clinical course, and distinct viral and nonviral causes make it an important model for studying interactions among infection, environmental carcinogenesis, and antitumor immunity.

Recognition, classification, and cellular identity

Cyril Toker described the tumor in 1972 as “trabecular carcinoma of the skin,” referring to the arrangement of malignant cells in cords and nests. Subsequent electron-microscopic studies identified dense-core neurosecretory granules, establishing neuroendocrine differentiation. The name Merkel cell carcinoma arose from similarities between the tumor cells and normal Merkel cells, specialized cells associated with light-touch sensation in the skin. Friedrich Sigmund Merkel had described those normal cells in 1875.

Normal Merkel cells occur chiefly in the basal epidermis and in specialized sensory structures, where they interact with nerve endings. They express epithelial proteins as well as neuroendocrine markers. MCC shares some of these characteristics, especially expression of cytokeratin 20 and neuroendocrine proteins. However, similarity of differentiation does not establish that every MCC originates from a mature Merkel cell. Most tumors are centered in the dermis rather than the epidermal compartment where normal Merkel cells reside, and the precise cell of origin remains unresolved.

MCC is classified as a high-grade neuroendocrine carcinoma. “Carcinoma” denotes epithelial differentiation, whereas “neuroendocrine” describes a pattern of cellular structure and protein expression associated with secretory and neuronal features. The designation does not imply that the tumor usually produces a clinically important hormone. Hormonal syndromes are not a typical feature of MCC, unlike those associated with some other neuroendocrine neoplasms.

The discovery of Merkel cell polyomavirus in 2008 by a team led by Yuan Chang and Patrick Moore transformed understanding of the disease. Viral sequences were identified in tumors using molecular methods, and integration of viral DNA into the tumor genome supported a causal role. Subsequent work established that virus-positive and virus-negative tumors can look very similar under the microscope while differing substantially in their initiating mechanisms and genomic profiles.

Modern classification therefore incorporates both morphology and biological context. MCC is distinct from metastatic small-cell carcinoma originating in the lung or another organ, even when the tumors share a small-blue-cell appearance. Rare combined cutaneous tumors contain both MCC and another component, particularly squamous cell carcinoma; these are commonly associated with ultraviolet damage and absence of detectable tumor-associated virus. Classification matters because the origin and extent of a neuroendocrine carcinoma determine staging, treatment, and interpretation of molecular findings.

Epidemiology and risk factors

MCC is uncommon compared with basal cell carcinoma, cutaneous squamous cell carcinoma, or melanoma. Its incidence varies substantially by geography, age distribution, population ancestry, and case ascertainment. A United States population-based analysis reported an increase from approximately 0.5 cases per 100,000 people in 2000 to 0.7 per 100,000 in 2013, with approximately 2,500 cases estimated nationally for 2013. These figures describe a particular historical population and should not be interpreted as a universal or current worldwide rate.

Age is one of the strongest associations. Most diagnoses occur in older adults, typically in the seventh or eighth decade of life, and incidence rises steeply with advancing age. MCC is more frequently diagnosed in men and in fair-skinned populations. It is uncommon in children and young adults, although cases occur, particularly in the setting of immune dysfunction. Population aging, improved pathological recognition, and changes in exposure and susceptibility all complicate interpretation of increasing recorded incidence.

Ultraviolet exposure is a major etiological factor. Tumors often arise on the head, neck, and upper limbs, and ultraviolet-associated DNA damage is especially prominent in virus-negative disease. Geographic comparisons are informative: Australian series have generally shown a larger proportion of virus-negative tumors than many North American and European series. Viral positivity is therefore not a fixed worldwide percentage; reported proportions depend on location and on how viral involvement is tested.

Immunosuppression is another major risk factor. Increased incidence is documented among solid-organ transplant recipients, people with HIV infection, and patients with certain hematological malignancies, particularly chronic lymphocytic leukemia. These associations are consistent with a role for cellular immune surveillance in restraining virus-associated and ultraviolet-damaged malignant cells. Immunosuppression is also associated with less favorable outcomes after diagnosis, although risks differ among underlying conditions and treatments.

Merkel cell polyomavirus infection itself is common, whereas MCC is rare. Many healthy adults have antibodies indicating previous exposure, and the virus can be detected on normal skin. Infection alone is therefore insufficient to explain tumor development. Additional events—including viral integration, tumor-specific alterations of viral proteins, aging, and immune escape—are required in virus-driven cancer. MCC is not transmitted from one person to another by ordinary contact, and the presence of the cancer does not imply a recently acquired infection.

Viral and ultraviolet-driven carcinogenesis

Virus-positive MCC depends on persistent expression of viral tumor antigens. In these tumors, viral DNA is usually integrated into the host-cell genome. Evidence that integration is clonal indicates that it occurred before expansion of the malignant cell population. Tumor-associated viral genomes typically contain mutations that truncate large T antigen, disabling its ability to support normal viral replication while preserving functions that promote malignant growth.

An important retained function is interference with the retinoblastoma protein, a major regulator of the cell cycle. Viral large T antigen disrupts this regulatory pathway, allowing inappropriate cell-cycle progression. Small T antigen contributes through additional effects on protein stability, translation, and growth-related signaling. The cancer therefore does not require productive viral infection in the ordinary sense: it depends on expression of selected viral proteins that alter cellular control mechanisms.

Virus-positive tumors generally have a relatively low burden of somatic DNA mutations compared with virus-negative MCC. Their foreign viral proteins nevertheless provide recognizable targets for T cells. Tumors that persist must evade or suppress these immune responses. Mechanisms include reduced antigen presentation, altered immune-cell recruitment, and activation of inhibitory signaling pathways. These interactions help explain why MCC can be highly immunogenic yet still progress rapidly.

Virus-negative MCC usually has a high tumor mutational burden, often with a characteristic ultraviolet mutational signature. This includes cytosine-to-thymine substitutions at dipyrimidine sites and tandem substitutions associated with ultraviolet injury. Inactivation of tumor-suppressor pathways involving TP53 and RB1 is common. In broad terms, ultraviolet-associated tumors reach disruption of cell-cycle control through host-genome mutations, whereas virus-positive tumors can achieve related functional effects through viral proteins.

The two pathways converge on uncontrolled proliferation and a neuroendocrine phenotype but differ in the antigens available for immune recognition. Virus-positive tumors express viral antigens; virus-negative tumors may express numerous mutation-derived neoantigens. This provides a biological basis for responses to immune checkpoint inhibitors in both groups. Viral status is not, by itself, a reliable rule for selecting or excluding patients from checkpoint therapy.

Neither pathway fully explains the tumor’s cellular origin. Proposed models include transformation of an epithelial progenitor with subsequent neuroendocrine differentiation, and experimental findings support lineage plasticity. The relation between precursor cell, viral integration, ultraviolet injury, and acquisition of the final tumor phenotype remains an active field of investigation. A clear distinction is therefore necessary between the well-supported causes of many MCCs and the still-unsettled identity of the initiating cell.

Clinical appearance and patterns of spread

The characteristic primary lesion is a firm, rapidly growing, painless nodule. It may be red, pink, violaceous, or close to normal skin color, and its surface is often smooth and shiny. Some lesions ulcerate, but ulceration is not necessary for diagnosis. The tumor commonly develops on sun-exposed skin of the head and neck or extremities, although the trunk, buttocks, and other relatively protected sites can also be affected.

Clinical recognition is difficult because the appearance is not specific. MCC can resemble a cyst, an inflamed follicle, a vascular lesion, a benign skin nodule, or another malignancy. The mnemonic “AEIOU” was proposed from a clinical series to describe frequent features: asymptomatic or nontender, expanding rapidly, immune suppression, older than 50 years, and ultraviolet-exposed skin in a fair-skinned person. These features can raise clinical suspicion but do not constitute a diagnostic test, and their absence does not exclude the disease.

Local extension may involve the subcutaneous tissue and, in more advanced lesions, deeper structures. Tumor size alone does not capture its biological risk. Even a relatively small lesion can have microscopic spread to a lymph node. Regional disease may present as an enlarged node, while in-transit metastases appear in skin or subcutaneous tissue along lymphatic drainage pathways between the primary site and a regional nodal basin.

MCC has a strong tendency toward metastasis. Common distant sites include nonregional lymph nodes, skin and subcutaneous tissue, bone, lung, and liver. Other organs, including the brain, can be involved. Symptoms of metastatic disease depend on location and may be absent initially. The distinction between regional and distant spread is anatomical and has major consequences for staging; an involved node outside the expected regional drainage territory is not equivalent to a nearby regional node.

Some patients present with nodal MCC without an identifiable skin primary. Possible explanations include immune-mediated regression of a cutaneous lesion or an occult primary too small to detect. Such cases are not automatically classified as distant metastatic disease. When disease is confined to a regional nodal presentation, the staging framework recognizes the unknown-primary situation separately. Several series have reported more favorable outcomes for nodal disease of unknown primary than for comparable nodal disease with a known primary, potentially reflecting differences in immune control, although this association does not establish a single mechanism.

Histopathology and diagnostic distinction

Definitive diagnosis requires a biopsy and pathological examination. On routine sections, MCC typically forms sheets, nests, or trabeculae of small to intermediate-sized malignant cells within the dermis, often extending into subcutaneous tissue. The cells have scant cytoplasm, finely granular nuclear chromatin, and frequent mitotic figures. Apoptotic debris and necrosis may be conspicuous. The overlying epidermis is often spared, although involvement and combined epithelial components can occur.

These features place MCC among the “small round blue cell” tumors in histopathology. Morphology alone may not reliably distinguish it from lymphoma, metastatic small-cell carcinoma, melanoma with unusual morphology, or certain other poorly differentiated neoplasms. Immunohistochemistry is therefore central. Most MCCs express broad-spectrum cytokeratins and cytokeratin 20, commonly in a distinctive perinuclear dot-like pattern. Neuroendocrine differentiation is supported by markers such as synaptophysin, chromogranin, and INSM1.

No single stain is completely sensitive or specific. A minority of MCCs are cytokeratin-20 negative, and some marker patterns overlap with other tumors. Thyroid transcription factor 1 is usually negative in MCC and frequently positive in pulmonary small-cell carcinoma, but exceptions prevent its use as an absolute discriminator. Leukocyte markers support a diagnosis of lymphoma, while melanocytic markers help distinguish melanoma. Interpretation depends on a panel of stains together with the clinical setting and imaging findings.

Immunohistochemical detection of viral large T antigen can identify many virus-associated tumors. Molecular assays can also detect viral DNA, but detecting viral sequences is not always equivalent to demonstrating that the tumor is virus-driven, because low-level virus may be present in surrounding tissues. Assay sensitivity, sample quality, viral copy number, and the tested target influence results. Viral testing provides biological information but is not required to establish every otherwise convincing diagnosis.

A pathology report also supplies information relevant to local treatment and staging: tumor dimensions, peripheral and deep margin status, lymphovascular invasion, extension into deeper structures, and nodal involvement where sampled. Small deposits in sentinel nodes can require immunohistochemical detection. Distinguishing an occult nodal metastasis from an uninvolved node is clinically important because it changes the pathological stage.

The diagnostic process separates two questions: what the tumor is, and how far it has spread. Histological confirmation answers the first. Clinical examination, nodal evaluation, and appropriately selected imaging answer the second. A skin lesion with convincing MCC morphology should not be assumed to be localized solely because it is small or because no enlarged nodes are palpable.

Staging and prognosis

Cancer staging uses the tumor–node–metastasis framework. In the American Joint Committee on Cancer eighth-edition system, introduced for use in 2018, the primary tumor categories distinguish lesions measuring 2 cm or less, greater than 2 cm through 5 cm, and greater than 5 cm. Invasion into deep structures such as fascia, muscle, cartilage, or bone defines a higher primary-tumor category regardless of diameter. Skin and subcutaneous involvement alone are not equivalent to invasion of these deeper structures.

Stages I and II generally represent localized disease without regional nodal or distant metastasis, with distinctions based on primary-tumor features. Stage III denotes regional spread, including nodal disease and specified in-transit patterns, while stage IV denotes distant metastasis. Clinical and pathological staging are distinguished because a normal examination does not provide the same information as microscopic assessment of regional nodes.

Sentinel lymph-node biopsy samples the first draining node or nodes identified through lymphatic mapping. Among patients with clinically node-negative MCC, roughly one-quarter to one-third have occult nodal disease in many series, although the proportion varies with tumor and patient characteristics. Mapping can be technically difficult in the head and neck, where drainage may involve multiple basins. Previous surgery, altered drainage, and limitations in pathological sampling can contribute to false-negative results.

Cross-sectional and functional imaging can detect disease not apparent on examination. Positron emission tomography, commonly combined with computed tomography using fluorodeoxyglucose, is useful because MCC is often metabolically active. Computed tomography provides anatomical assessment, and magnetic resonance imaging has selected roles, including assessment of suspected central nervous system involvement. Imaging cannot reliably exclude every microscopic nodal deposit and therefore does not simply replace sentinel-node evaluation.

Prognosis depends strongly on stage, but age, immune status, competing illnesses, nodal disease burden, and treatment also matter. Historical population analyses show substantially better survival for localized than for distant disease. Such estimates require careful interpretation: overall survival includes deaths from unrelated causes, relative survival compares observed survival with population expectations, and disease-specific survival depends on attribution of cause of death. These measures are not interchangeable.

Recurrences are concentrated in the first several years after diagnosis, especially the first two to three years. Immunosuppression is an adverse prognostic factor, and pathological nodal information improves risk assessment. Historical survival statistics also incompletely represent modern advanced-disease outcomes because checkpoint inhibitors have produced durable responses in a subset of patients who previously had few effective systemic options.

Treatment of localized and regional disease

Treatment of potentially curable MCC combines control of the primary site with assessment and management of regional lymphatic disease. Surgery commonly involves excision of the primary tumor with histologically clear margins. Margins of approximately 1–2 cm are often used when anatomy and function permit, but the appropriate extent depends on site, reconstruction, planned radiation, and patient factors. A large defect is not automatically evidence of better oncological treatment, particularly where additional tissue removal would cause major functional harm.

Sentinel-node assessment is commonly performed before or at definitive primary surgery, because extensive excision or reconstruction can alter lymphatic mapping. When sentinel nodes contain tumor, regional treatment may involve nodal radiation therapy, lymph-node dissection, or a combination in selected circumstances. Clinically apparent nodal disease requires a different assessment from microscopic involvement discovered only by sentinel-node biopsy. The volume, distribution, and resectability of nodal disease influence treatment selection.

MCC is generally radiosensitive. Postoperative radiation can reduce local and regional recurrence, particularly when pathological or clinical features indicate increased risk. Radiation fields may encompass the primary tumor bed, a nodal basin, or both, depending on disease distribution and prior treatment. Conventional postoperative courses commonly use total doses in the approximate range of 50–60 gray, with higher doses sometimes used for residual disease; dose and fractionation vary by indication and technique.

Definitive radiation can provide local control when surgery is not performed because of tumor location, medical circumstances, or anticipated morbidity. Evidence for local and regional management includes many retrospective series rather than large randomized comparisons. Apparent survival benefits in observational studies can be influenced by patient selection, treatment access, stage, and other confounding factors. Improved local control and improved overall survival are related but distinct outcomes.

The consequences of treatment are important in an often older population. Surgery may require skin grafting or flap reconstruction, and nodal treatment can lead to lymphedema. Radiation may cause acute skin inflammation, discomfort, and fatigue, as well as later fibrosis or tissue changes. Head-and-neck treatment can affect nearby structures depending on the field. These effects are weighed against the risk of recurrence within multidisciplinary care.

Routine adjuvant cytotoxic chemotherapy has not established a survival benefit in completely resected localized disease and is not equivalent to treatment of measurable metastatic cancer. Immunotherapy before surgery or after definitive local treatment has been studied in clinical trials. These settings require their own evidence: efficacy in advanced disease does not by itself establish the balance of benefit and harm when no measurable tumor remains.

Systemic therapy for advanced disease

For unresectable recurrent or metastatic MCC, cancer immunotherapy has changed the treatment landscape. Antibodies targeting programmed cell death protein 1, or PD-1, or its ligand PD-L1 can release inhibitory signals that restrain antitumor T-cell activity. Unlike cytotoxic drugs, these agents do not primarily work by directly damaging dividing tumor cells. They depend on a functional immune response, which helps explain both durable tumor control in some patients and distinctive inflammatory toxicities.

Avelumab, an anti-PD-L1 antibody, received United States approval for metastatic MCC in 2017. In the previously treated cohort of the JAVELIN Merkel 200 study, approximately one-third of patients had an objective response, with a subset of responses persisting for years. This was clinically important because responses to earlier chemotherapy were often short-lived. The trial was single-arm, so its findings did not constitute a randomized head-to-head comparison with chemotherapy.

Pembrolizumab, an anti-PD-1 antibody, received United States approval in 2018 for recurrent locally advanced or metastatic MCC. In the 50-patient KEYNOTE-017 study of previously untreated advanced disease, the objective response rate was approximately 56%, with durable responses in a substantial fraction of responders. Responses occurred in both virus-positive and virus-negative tumors. Retifanlimab, another anti-PD-1 antibody, received United States approval in 2023 for adults with metastatic or recurrent locally advanced MCC; its pivotal study reported an objective response rate of about 52%. Regulatory indications differ by jurisdiction.

These response percentages should not be ranked as if they came from one comparative experiment. The studies differed in prior treatment, eligibility, follow-up, and patient characteristics. Objective response measures tumor shrinkage according to predefined criteria; it is not identical to cure, improvement in symptoms, or longer overall survival. Some patients have primary resistance, while others relapse after an initial response.

Checkpoint blockade can cause immune-mediated adverse effects in the skin, bowel, liver, lungs, endocrine organs, and other tissues. Solid-organ transplant recipients present a particular challenge because immune activation can precipitate transplant rejection. People with significant autoimmune disease or substantial immunosuppression were also underrepresented in many pivotal trials, limiting direct generalization of trial results to these groups.

Chemotherapy remains active against MCC, with regimens historically including platinum drugs plus etoposide. Initial tumor shrinkage can be substantial, but resistance commonly develops and responses are generally less durable than successful checkpoint responses. Cytotoxic treatment can also cause marrow suppression, infection risk, and other toxicity. After checkpoint-inhibitor resistance, approaches under investigation include alternative immune combinations, radiation-based combinations, and cell therapies; none should be treated as uniformly effective across this heterogeneous setting.

Surveillance, biomarkers, and research directions

Surveillance after treatment focuses on recurrence at the primary site, regional nodes, in-transit pathways, and distant organs. Clinical assessment includes the skin and relevant nodal basins. Imaging intensity varies with stage, immune status, symptoms, and the estimated probability of relapse. Because recurrence risk is concentrated early, surveillance is usually more intensive during the first few years. The benefit of detecting asymptomatic recurrence must be considered separately from the ability of a test simply to identify more abnormalities.

Serological testing for antibodies against Merkel cell polyomavirus oncoproteins is an established biomarker approach in a subset of patients. These antibodies differ from antibodies to viral capsid proteins, which are common in the general population and mainly indicate previous exposure. Only a proportion of patients with MCC produce detectable oncoprotein antibodies at diagnosis. In those who do, falling titers after treatment and rising titers during follow-up can provide information about disease activity.

Interpretation depends on the baseline result and the assay used. A person who does not produce detectable oncoprotein antibodies cannot be monitored meaningfully through serial changes in that marker. A positive or rising result does not localize a tumor, and an apparently reassuring result cannot exclude every recurrence. Viral antibody testing therefore complements clinical and radiological assessment rather than functioning as a stand-alone determination of disease status.

Circulating tumor DNA is another important research and clinical-development area. Tumor-informed assays identify mutations in an individual’s cancer and then search for corresponding DNA fragments in blood. This approach can potentially monitor both virus-positive and virus-negative disease. Prospective studies have shown associations between detectable circulating tumor DNA and recurrence risk, but assay performance depends on tumor burden, sampling time, analytical methods, and thresholds. Whether a biomarker-guided intervention improves outcomes requires evidence beyond an association with relapse.

Predicting response to immunotherapy remains difficult. Viral status, PD-L1 expression, and tumor mutational burden provide biological information but do not divide patients cleanly into responders and nonresponders. Tumor-infiltrating lymphocytes, antigen presentation, T-cell specificity, and the immune microenvironment are being investigated to explain resistance. Research on viral antigens is particularly attractive because these proteins can be shared tumor targets without being normal human cellular proteins.

Other studies examine neoadjuvant checkpoint blockade, adjuvant systemic treatment, combinations with radiation, and adoptive cell therapy directed against viral antigens. Rare-disease research must contend with small eligible populations and rapidly changing standards of care. International collaboration, prospective registries, and carefully designed trials are important for distinguishing durable clinical benefit from promising pathological responses or biomarker changes alone.